PROCEPT BioRobotics lowered its 2026 U.S. procedure guidance to a range of 54,000 to 56,000, down from the prior 60,000 to 64,000, while reiterating full-year revenue guidance of $390 million to $410 million and maintaining its expectation for positive adjusted EBITDA in the fourth quarter of 2026. The company reported second-quarter total revenue of $94.5 million, a 19% year-over-year increase, with U.S. revenue of $83.4 million and international revenue of $11.1 million. U.S. procedures grew 21% to over 13,100, but fell short of expectations due to concentrated softness in legacy AQUABEAM accounts, prompting an accelerated push to upgrade those systems to HYDROS. PROCEPT placed 65 HYDROS systems during the quarter at an average selling price of approximately $495,000, up from $485,000 in the first quarter, and recorded a net loss of $26.9 million with an adjusted EBITDA loss of $11.3 million. Management expects to complete roughly 40 replacement sales at the midpoint of its revenue guidance, with replacement system pricing of $300,000 to $325,000, and sees the replacement cycle remaining a significant factor into 2027.
Procept Biorobotics CorpLowered 2026 U.S. procedure guidance due to softness in legacy AQUABEAM accounts, indicating weaker demand for those systems.
